These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34686528)

  • 21. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal microbiota drive CRPC.
    Fenner A
    Nat Rev Urol; 2021 Dec; 18(12):705. PubMed ID: 34732851
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.
    Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The concept and mechanisms of castration-resistant prostate cancer].
    Naito S; Shiota M
    Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
    Grist E; de Bono JS; Attard G
    J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
    Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
    Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
    Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
    Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
    Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
    Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
    Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
    Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
    Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Androgen receptor variants in prostate cancer].
    Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
    Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.